Lpath, Inc. (LPTN) Issued Patent Related to Ocular Drug Program iSONEP
Lpath is a therapeutic antibody company and the category leader in lipid-targeted therapeutics. The company ImmuneY2 drug discovery engine has the unique ability to generate monoclonal antibodies that bind to and inhibit bioactive lipids that contribute to disease. Lpath has three drug candidates currently: Lpathomab, ASONEP, and iSONEP. The company announced today that it has received official notification from the U.S. Patent and Trademark Office that it has been issued a key patent supporting its iSONEP program. The new patent claims methods of using monoclonal antibodies (including iSONEP) that bind sphingosine-1-phosphate (S1P) in the treatment of a wide variety of…